EP1147204A1
(en)
*
|
1999-01-28 |
2001-10-24 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
|
DE19956568A1
(en)
*
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Method and medicament for inhibiting the expression of a given gene
|
US8541548B2
(en)
*
|
1999-06-07 |
2013-09-24 |
Arrowhead Madison Inc. |
Compounds and methods for reversible modification of biologically active molecules
|
US20080281041A1
(en)
*
|
1999-06-07 |
2008-11-13 |
Rozema David B |
Reversibly Masked Polymers
|
GB9925459D0
(en)
*
|
1999-10-27 |
1999-12-29 |
Plant Bioscience Ltd |
Gene silencing
|
US7829693B2
(en)
*
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
DE10100586C1
(en)
*
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases
|
ES2381775T3
(en)
|
2000-08-04 |
2012-05-31 |
Dmi Biosciences, Inc. |
Procedure of the use of diketopiperazines and their composition
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
US7423142B2
(en)
*
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7767802B2
(en)
*
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US20050153915A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
|
US20050164966A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
DE10163098B4
(en)
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Method for inhibiting the replication of viruses
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
US20040121348A1
(en)
*
|
2001-10-26 |
2004-06-24 |
Ribopharma Ag |
Compositions and methods for treating pancreatic cancer
|
DE10230997A1
(en)
*
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Drug to increase the effectiveness of a receptor-mediates apoptosis in drug that triggers tumor cells
|
US20040063654A1
(en)
*
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
DE10202419A1
(en)
*
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Method of inhibiting expression of a target gene resulting from chromosome aberration
|
US20050096289A1
(en)
*
|
2002-02-07 |
2005-05-05 |
Hans Prydz |
Methods and compositions for modulating tissue factor
|
US20030157573A1
(en)
*
|
2002-02-12 |
2003-08-21 |
Orna Mor |
Use of Axl receptor for diagnosis and treatment of renal disease
|
WO2003072637A1
(en)
*
|
2002-02-22 |
2003-09-04 |
Insert Therapeutics, Inc. |
Carbohydrate-modified polymers, compositions and uses related thereto
|
US8008355B2
(en)
*
|
2002-03-11 |
2011-08-30 |
Roche Madison Inc. |
Endosomolytic poly(vinyl ether) polymers
|
US8138383B2
(en)
*
|
2002-03-11 |
2012-03-20 |
Arrowhead Madison Inc. |
Membrane active heteropolymers
|
MXPA05002444A
(en)
|
2002-09-06 |
2005-09-30 |
Insert Therapeutics Inc |
Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto.
|
US7635770B2
(en)
*
|
2002-11-14 |
2009-12-22 |
Dharmacon, Inc. |
siRNA targeting protein kinase N-3 (PKN-3)
|
US20100113307A1
(en)
*
|
2002-11-14 |
2010-05-06 |
Dharmacon, Inc. |
siRNA targeting vascular endothelial growth factor (VEGF)
|
US9719094B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting SEC61G
|
US7592442B2
(en)
*
|
2002-11-14 |
2009-09-22 |
Dharmacon, Inc. |
siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
|
US7619081B2
(en)
*
|
2002-11-14 |
2009-11-17 |
Dharmacon, Inc. |
siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
EP2284266B1
(en)
*
|
2002-11-14 |
2013-11-06 |
Thermo Fisher Scientific Biosciences Inc. |
siRNA targeting tp53
|
US20080268457A1
(en)
*
|
2002-11-14 |
2008-10-30 |
Dharmacon, Inc. |
siRNA targeting forkhead box P3 (FOXP3)
|
US8198427B1
(en)
|
2002-11-14 |
2012-06-12 |
Dharmacon, Inc. |
SiRNA targeting catenin, beta-1 (CTNNB1)
|
US7977471B2
(en)
*
|
2002-11-14 |
2011-07-12 |
Dharmacon, Inc. |
siRNA targeting TNFα
|
US9719092B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting CNTD2
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
US9771586B2
(en)
|
2002-11-14 |
2017-09-26 |
Thermo Fisher Scientific Inc. |
RNAi targeting ZNF205
|
US7951935B2
(en)
|
2002-11-14 |
2011-05-31 |
Dharmacon, Inc. |
siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
|
US7691998B2
(en)
*
|
2002-11-14 |
2010-04-06 |
Dharmacon, Inc. |
siRNA targeting nucleoporin 62kDa (Nup62)
|
US7781575B2
(en)
|
2002-11-14 |
2010-08-24 |
Dharmacon, Inc. |
siRNA targeting tumor protein 53 (p53)
|
US20090227780A1
(en)
*
|
2002-11-14 |
2009-09-10 |
Dharmacon, Inc. |
siRNA targeting connexin 43
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US7612196B2
(en)
*
|
2002-11-14 |
2009-11-03 |
Dharmacon, Inc. |
siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
|
EP2799114A3
(en)
|
2003-05-15 |
2015-02-18 |
Ampio Pharmaceuticals, Inc. |
Treatment of T-cell mediated diseases
|
US20050019806A1
(en)
*
|
2003-06-30 |
2005-01-27 |
Horvitz H. Robert |
Nucleic acids and polypeptides required for cell survival in the absence of Rb
|
US20050136437A1
(en)
*
|
2003-08-25 |
2005-06-23 |
Nastech Pharmaceutical Company Inc. |
Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
|
WO2005045032A2
(en)
*
|
2003-10-20 |
2005-05-19 |
Sima Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF EARLY GROWTH RESPONSE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2005051431A1
(en)
*
|
2003-11-25 |
2005-06-09 |
The University Of York |
Colloidal delivery system for biological therapeutic agents
|
WO2005084180A2
(en)
*
|
2003-12-19 |
2005-09-15 |
University Of Cincinnati |
Polyamides and polyamide complexes for delivery of oligonucleotide decoys
|
US7807814B2
(en)
*
|
2003-12-23 |
2010-10-05 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for combined therapy of disease
|
WO2005080410A1
(en)
*
|
2004-02-20 |
2005-09-01 |
Genesis Research And Development Corporation Limited |
Targeted delivery of rna interference molecules for the treatment of ige-mediated disorders
|
EP1737956A2
(en)
*
|
2004-03-01 |
2007-01-03 |
Massachusetts Institute of Technology |
Rnai-based therapeutics for allergic rhinitis and asthma
|
US20050202075A1
(en)
*
|
2004-03-12 |
2005-09-15 |
Pardridge William M. |
Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers
|
JP2005264046A
(en)
*
|
2004-03-19 |
2005-09-29 |
Sony Corp |
Stimulation-responsive hydrogel, method for producing stimulation-responsive hydrogel, and polymer actuator using stimulation-responsive hydrogel
|
US20050267300A1
(en)
|
2004-04-05 |
2005-12-01 |
Muthiah Manoharan |
Processes and reagents for oligonucleotide synthesis and purification
|
EP1586654A1
(en)
*
|
2004-04-15 |
2005-10-19 |
Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg |
Replication competent viruses capable of silencing virus inhibitory factor expression
|
US20050260652A1
(en)
*
|
2004-04-15 |
2005-11-24 |
The General Hospital Corporation |
Compositions and methods that modulate RNA interference
|
US20110206639A1
(en)
*
|
2004-04-15 |
2011-08-25 |
Christie Vermeulen |
Replication competent viruses capable of silencing virus inhibitory factor expression
|
CA2562685C
(en)
*
|
2004-04-27 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
|
CA2562151C
(en)
*
|
2004-04-30 |
2016-09-06 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a c5-modified pyrimidine
|
US7605250B2
(en)
*
|
2004-05-12 |
2009-10-20 |
Dharmacon, Inc. |
siRNA targeting cAMP-specific phosphodiesterase 4D
|
US20050265927A1
(en)
*
|
2004-05-17 |
2005-12-01 |
Yale University |
Intranasal delivery of nucleic acid molecules
|
WO2005115455A2
(en)
*
|
2004-05-17 |
2005-12-08 |
Combinatorx, Incorporated |
Methods and reagents for the treatment of immunoinflammatory disorders
|
EP2471923B1
(en)
|
2004-05-28 |
2014-08-20 |
Asuragen, Inc. |
Methods and compositions involving microRNA
|
US8815599B2
(en)
*
|
2004-06-01 |
2014-08-26 |
Pronai Therapeutics, Inc. |
Methods and compositions for the inhibition of gene expression
|
US20060040290A1
(en)
*
|
2004-06-23 |
2006-02-23 |
Applera Corporation |
Methods, compositions, and kits comprising PNA for RNA interference
|
US7615618B2
(en)
*
|
2004-06-30 |
2009-11-10 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a non-phosphate backbone linkage
|
US8361976B2
(en)
|
2004-07-09 |
2013-01-29 |
University Of Massachusetts |
Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules
|
WO2006085987A2
(en)
*
|
2004-07-09 |
2006-08-17 |
University Of Iowa Research Foundation |
Rna interference in respiratory epitheial cells
|
EP1828215A2
(en)
|
2004-07-21 |
2007-09-05 |
Alnylam Pharmaceuticals Inc. |
Oligonucleotides comprising a modified or non-natural nucleobase
|
CA2573671A1
(en)
*
|
2004-07-21 |
2006-02-23 |
Medtronic, Inc. |
Methods for reducing or preventing localized fibrosis using sirna
|
US20060063208A1
(en)
|
2004-08-02 |
2006-03-23 |
Woolf Clifford J |
DRG11-responsive (DRAGON) gene and uses thereof
|
AU2005330637B2
(en)
|
2004-08-04 |
2012-09-20 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
|
EP1799825B1
(en)
*
|
2004-10-05 |
2011-06-29 |
The California Institute of Technology |
Aptamer regulated nucleic acids and uses thereof
|
WO2006062581A2
(en)
*
|
2004-10-15 |
2006-06-15 |
Benitec, Inc. |
Delivery of therapeutic rnai agents for treating restenosis
|
US20060115455A1
(en)
*
|
2004-10-22 |
2006-06-01 |
Reed Kenneth C |
Therapeutic RNAi agents for treating psoriasis
|
EP2302051B1
(en)
|
2004-11-12 |
2015-01-07 |
Asuragen, Inc. |
Methods and compositions involving miRNA and miRNA inhibitor molecules
|
DE102005003788A1
(en)
*
|
2005-01-19 |
2006-07-20 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
siRNA molecules for the treatment of blood vessels
|
EP1841867A1
(en)
*
|
2005-01-24 |
2007-10-10 |
Avaris AB |
COMPLEX CONTAINING SiRNA, ShRNA OR ANTISENSE MOLECULE AND FUNCTIONAL ENTITY, FOR IMPROVED SPECIFICITY AND DELIVERY
|
US20090011003A1
(en)
*
|
2005-01-28 |
2009-01-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Composition for Suppressing Expression of Target Gene
|
WO2006086681A2
(en)
|
2005-02-09 |
2006-08-17 |
Beth Israel Deaconess Medical Center, Inc. |
Methods of inhibiting smooth muscle cell migration and proliferation
|
EP2551282A3
(en)
|
2005-03-23 |
2013-02-13 |
Genmab A/S |
Antibodies against CD38 for treatment of multiple myeloma
|
JP4131271B2
(en)
*
|
2005-03-30 |
2008-08-13 |
ソニー株式会社 |
Information processing apparatus and method, and program
|
US20070033062A1
(en)
*
|
2005-04-28 |
2007-02-08 |
Oligoengine, Inc. |
Business methods, systems, and computer programs for designing customized biological assays and producing related catalogs and kits
|
JP2008201673A
(en)
*
|
2005-05-16 |
2008-09-04 |
Kyushu Univ |
Rna-containing composition
|
ES2405357T3
(en)
*
|
2005-05-25 |
2013-05-30 |
Cellmid Limited |
Pharmaceutical composition for occlusive vasculopathy.
|
CA2612200A1
(en)
*
|
2005-06-15 |
2006-12-21 |
London Health Sciences Centre Research Inc. |
Method of cancer treatment using sirna silencing
|
US8093369B2
(en)
*
|
2005-10-11 |
2012-01-10 |
Ben Gurion University Of The Negev Research And Development Authority Ltd. |
Compositions for silencing the expression of VDAC1 and uses thereof
|
TW200800235A
(en)
|
2005-10-18 |
2008-01-01 |
Otsuka Pharma Co Ltd |
Carrier composition for nucleic acid transport
|
JP5336853B2
(en)
|
2005-11-02 |
2013-11-06 |
プロチバ バイオセラピューティクス インコーポレイティッド |
Modified siRNA molecules and methods of use thereof
|
US8367628B2
(en)
*
|
2005-12-01 |
2013-02-05 |
Pronai Therapeutics, Inc. |
Amphoteric liposome formulation
|
US20090317802A1
(en)
*
|
2005-12-09 |
2009-12-24 |
Bhatia Sangeeta N |
Compositions and Methods to Monitor RNA Delivery to Cells
|
CA2633063A1
(en)
*
|
2005-12-16 |
2007-06-21 |
Diatos |
Cell penetrating peptide conjugates for delivering of nucleic acids intocells
|
US20070172430A1
(en)
*
|
2006-01-20 |
2007-07-26 |
Nastech Pharmaceutical Company Inc. |
Dry powder compositions for rna influenza therapeutics
|
US8323967B2
(en)
*
|
2006-04-05 |
2012-12-04 |
Joslin Diabetes Center, Inc. |
Enhancing stem cell mobilization
|
US20070276134A1
(en)
*
|
2006-05-24 |
2007-11-29 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for complexes of nucleic acids and organic cations
|
US8501478B2
(en)
*
|
2006-06-15 |
2013-08-06 |
University Of Cincinnati |
Trehalose click polymers for delivery of biologically active molecules
|
CN101500548A
(en)
*
|
2006-08-18 |
2009-08-05 |
弗·哈夫曼-拉罗切有限公司 |
Polyconjugates for in vivo delivery of polynucleotides
|
US8017109B2
(en)
*
|
2006-08-18 |
2011-09-13 |
Roche Madison Inc. |
Endosomolytic poly(acrylate) polymers
|
JP2010504350A
(en)
*
|
2006-09-19 |
2010-02-12 |
アシュラジェン インコーポレイテッド |
Genes and pathways regulated by miR-200 as targets for therapeutic intervention
|
US8158595B2
(en)
|
2006-11-09 |
2012-04-17 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
WO2008073856A2
(en)
*
|
2006-12-08 |
2008-06-19 |
Massachusetts Institute Of Technology |
Delivery of nanoparticles and/or agents to cells
|
JP2010516625A
(en)
|
2007-01-24 |
2010-05-20 |
インサート セラピューティクス, インコーポレイテッド |
Polymer-drug conjugates with tether groups for controlled drug delivery
|
US20090060889A1
(en)
|
2007-03-12 |
2009-03-05 |
Von Hofe Eric |
Ii-RNAi involved Ii suppression in cancer immunotherapy
|
US8133553B2
(en)
|
2007-06-18 |
2012-03-13 |
Zimmer, Inc. |
Process for forming a ceramic layer
|
US8309521B2
(en)
|
2007-06-19 |
2012-11-13 |
Zimmer, Inc. |
Spacer with a coating thereon for use with an implant device
|
GB0711952D0
(en)
*
|
2007-06-20 |
2007-08-01 |
King S College London |
Microspheres
|
WO2009011855A2
(en)
*
|
2007-07-16 |
2009-01-22 |
California Institute Of Technology |
Selection of nucleic acid-based sensor domains within nucleic acid switch platform
|
US8367815B2
(en)
*
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
US8865667B2
(en)
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
EP2198050A1
(en)
|
2007-09-14 |
2010-06-23 |
Asuragen, INC. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
US8608049B2
(en)
|
2007-10-10 |
2013-12-17 |
Zimmer, Inc. |
Method for bonding a tantalum structure to a cobalt-alloy substrate
|
UA97559C2
(en)
|
2007-11-08 |
2012-02-27 |
Оцука Фармасьютікал Ко., Лтд. |
Nucleic acid complex and a nucleic acid delivery composition
|
US8071562B2
(en)
|
2007-12-01 |
2011-12-06 |
Mirna Therapeutics, Inc. |
MiR-124 regulated genes and pathways as targets for therapeutic intervention
|
US9029524B2
(en)
*
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
FR2925491B1
(en)
*
|
2007-12-19 |
2010-09-03 |
Oz Biosciences Sas |
NEW CLASSES OF CATIONIC LIPIDS FOR THE TRANSPORT OF ACTIVE AGENTS IN CELLS
|
WO2009082817A1
(en)
|
2007-12-27 |
2009-07-09 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering rna
|
EP3643782A1
(en)
|
2008-02-11 |
2020-04-29 |
Phio Pharmaceuticals Corp. |
Modified rnai polynucleotides and uses thereof
|
FR2928373B1
(en)
|
2008-03-05 |
2010-12-31 |
Centre Nat Rech Scient |
LINEAR POLYETHYLENIMINE DERIVATIVE POLYMER FOR GENE TRANSFER.
|
US20090226531A1
(en)
*
|
2008-03-07 |
2009-09-10 |
Allergan, Inc. |
Methods and composition for intraocular delivery of therapeutic sirna
|
EP2281041B1
(en)
|
2008-04-15 |
2014-07-02 |
Protiva Biotherapeutics Inc. |
Silencing of csn5 gene expression using interfering rna
|
US8258111B2
(en)
|
2008-05-08 |
2012-09-04 |
The Johns Hopkins University |
Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
|
JP5856843B2
(en)
|
2008-05-27 |
2016-02-10 |
アンピオ ファーマシューティカルズ,インコーポレイテッド |
Pharmaceutical composition using diketopiperazine
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
WO2010033246A1
(en)
|
2008-09-22 |
2010-03-25 |
Rxi Pharmaceuticals Corporation |
Rna interference in skin indications
|
CA2962219C
(en)
*
|
2008-10-22 |
2020-08-25 |
Quark Pharmaceuticals, Inc. |
Methods for treating eye disorders
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
WO2010101226A1
(en)
*
|
2009-03-04 |
2010-09-10 |
大塚製薬株式会社 |
Nucleic acid complex and nucleic acid-delivering composition
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
US20110009478A1
(en)
*
|
2009-07-08 |
2011-01-13 |
Reineke Theresa M |
Theranostic polycation beacons comprising oligoethyleneamine repeating units and lanthanide chelates
|
CN101624596B
(en)
*
|
2009-08-12 |
2011-01-26 |
广州金琪基因技术研究发展中心 |
External guide sequence of target c-myc cancer gene
|
US9468650B2
(en)
|
2009-09-16 |
2016-10-18 |
Duke University |
Inhibition of endosomal toll-like receptor activation
|
US9799416B2
(en)
*
|
2009-11-06 |
2017-10-24 |
Terrapower, Llc |
Methods and systems for migrating fuel assemblies in a nuclear fission reactor
|
EP2539451B1
(en)
*
|
2010-02-24 |
2016-01-06 |
Arrowhead Research Corporation |
Compositions for targeted delivery of sirna
|
EP2550001B1
(en)
|
2010-03-24 |
2019-05-22 |
Phio Pharmaceuticals Corp. |
Rna interference in ocular indications
|
WO2011119852A1
(en)
|
2010-03-24 |
2011-09-29 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering rnai compounds
|
IL265674B2
(en)
|
2010-03-24 |
2024-05-01 |
Phio Pharm Corp |
Rna interference in dermal and fibrotic indications
|
CA2802994A1
(en)
|
2010-06-17 |
2011-12-22 |
The United States Of America As Represented By The Secretary, National I Nstitutes Of Health |
Compositions and methods for treating inflammatory conditions
|
WO2012033792A2
(en)
|
2010-09-07 |
2012-03-15 |
Dmi Acquisition Corp. |
Treatment of diseases
|
AU2012267578B2
(en)
|
2011-06-08 |
2017-04-20 |
Translate Bio, Inc. |
Cleavable lipids
|
WO2013040251A2
(en)
|
2011-09-13 |
2013-03-21 |
Asurgen, Inc. |
Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
|
MY167804A
(en)
|
2011-10-10 |
2018-09-26 |
Ampio Pharmaceuticals Inc |
Treatment of degenerative joint disease
|
MX2014003856A
(en)
|
2011-10-10 |
2015-01-16 |
Ampio Pharmaceuticals Inc |
Implantable medical devices with increased immune tolerance, and methods for making and implanting.
|
EP2771007B1
(en)
|
2011-10-28 |
2018-04-04 |
Ampio Pharmaceuticals, Inc. |
Treatment of rhinitis
|
WO2013075132A1
(en)
|
2011-11-17 |
2013-05-23 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Therapeutic rna switches compositions and methods of use
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
NZ625980A
(en)
*
|
2012-01-04 |
2015-05-29 |
Quark Pharmaceuticals Inc |
Double-stranded rna compounds to casp2 and uses thereof
|
BR112014021068A8
(en)
|
2012-02-21 |
2018-01-23 |
Centre National De La Recherce Scient |
inhibitor of an interaction between phosphatidylserine and a thymic receptor, pharmaceutical composition and use of an inhibitor
|
US20160015808A1
(en)
|
2012-02-21 |
2016-01-21 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Tam receptors as virus entry cofactors
|
AU2013273504B2
(en)
*
|
2012-06-08 |
2017-12-07 |
Ethris Gmbh |
Pulmonary delivery of messenger RNA
|
CA2875391A1
(en)
|
2012-07-27 |
2014-01-30 |
Institut National De La Sante Et De La Recherche Medicale |
Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
|
WO2014055493A1
(en)
|
2012-10-02 |
2014-04-10 |
Cerulean Pharma Inc. |
Methods and systems for polymer precipitation and generation of particles
|
KR102170266B1
(en)
*
|
2013-02-27 |
2020-10-27 |
한국과학기술원 |
GRAFTED CONJUGATES OF POLYSACCHARIDES AND siRNAs, siRNA DELIVERY SYSTEM COMPRISING THE SAME AND PREPARING METHOD THEREOF
|
WO2014160211A1
(en)
*
|
2013-03-13 |
2014-10-02 |
Isis Pharmaceuticals, Inc. |
Modulation of inflammatory responses by c-reactive protein
|
JP6588005B2
(en)
|
2013-03-15 |
2019-10-09 |
アンピオ ファーマシューティカルズ,インコーポレイテッド |
Pharmaceutical composition used to stimulate cartilage formation
|
JP6772062B2
(en)
|
2013-12-02 |
2020-10-21 |
フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. |
Cancer immunotherapy
|
US20160304875A1
(en)
|
2013-12-04 |
2016-10-20 |
Rxi Pharmaceuticals Corporation |
Methods for treatment of wound healing utilizing chemically modified oligonucleotides
|
US9752145B2
(en)
|
2014-03-17 |
2017-09-05 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Compositions and methods for reducing C/EBP homologous protein activity in myeloid-derived suppressor cells
|
EP3137119B1
(en)
|
2014-04-28 |
2020-07-01 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using a nucleic acid targeting mdm2
|
JP2017514908A
(en)
|
2014-05-01 |
2017-06-08 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
Methods for the treatment of disorders in the front of the eye utilizing nucleic acid molecules
|
RU2736513C2
(en)
|
2014-08-18 |
2020-11-17 |
Ампио Фармасьютикалз, Инк. |
Treating pathological conditions of joints
|
KR102506169B1
(en)
|
2014-09-05 |
2023-03-08 |
피오 파마슈티칼스 코프. |
Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
|
CN107208095B
(en)
|
2014-10-02 |
2021-11-16 |
阿布特斯生物制药公司 |
Compositions and methods for silencing hepatitis b virus gene expression
|
US20180245074A1
(en)
|
2015-06-04 |
2018-08-30 |
Protiva Biotherapeutics, Inc. |
Treating hepatitis b virus infection using crispr
|
US11389512B2
(en)
|
2015-06-22 |
2022-07-19 |
Ampio Pharmaceuticals, Inc. |
Use of low molecular weight fractions of human serum albumin in treating diseases
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
WO2017007813A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
EP3329003A2
(en)
|
2015-07-29 |
2018-06-06 |
Arbutus Biopharma Corporation |
Compositions and methods for silencing hepatitis b virus gene expression
|
WO2017070151A1
(en)
|
2015-10-19 |
2017-04-27 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
|
US20200123499A1
(en)
|
2015-12-02 |
2020-04-23 |
Massachusetts Institute Of Technology |
Method for efficient generation of neurons from non-neuronal cells
|
EP4233989A3
(en)
|
2017-06-07 |
2023-10-11 |
Shifamed Holdings, LLC |
Intravascular fluid movement devices, systems, and methods of use
|
WO2019094963A1
(en)
|
2017-11-13 |
2019-05-16 |
Shifamed Holdings, Llc |
Intravascular fluid movement devices, systems, and methods of use
|
WO2019101882A1
(en)
|
2017-11-23 |
2019-05-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating dengue virus infection
|
CN117959583A
(en)
|
2018-02-01 |
2024-05-03 |
施菲姆德控股有限责任公司 |
Intravascular blood pump and methods of use and manufacture
|
JP2022540616A
(en)
|
2019-07-12 |
2022-09-16 |
シファメド・ホールディングス・エルエルシー |
Intravascular blood pump and methods of manufacture and use
|
WO2021016372A1
(en)
|
2019-07-22 |
2021-01-28 |
Shifamed Holdings, Llc |
Intravascular blood pumps with struts and methods of use and manufacture
|
US11724089B2
(en)
|
2019-09-25 |
2023-08-15 |
Shifamed Holdings, Llc |
Intravascular blood pump systems and methods of use and control thereof
|
JP2023501445A
(en)
|
2019-11-08 |
2023-01-18 |
フィオ ファーマシューティカルズ コーポレーション |
Chemically modified oligonucleotides targeting bromodomain-containing protein 4 (BRD4) for immunotherapy
|
EP4085136A1
(en)
|
2019-12-31 |
2022-11-09 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides with improved systemic delivery
|
WO2021236852A1
(en)
|
2020-05-20 |
2021-11-25 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
WO2022047316A1
(en)
|
2020-08-28 |
2022-03-03 |
Sana Biotechnology, Inc. |
Modified anti-viral binding agents
|
WO2023015265A2
(en)
|
2021-08-04 |
2023-02-09 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides
|
WO2023015264A1
(en)
|
2021-08-04 |
2023-02-09 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
|